Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma

about

Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma

Item

http://www.wikidata.org/entity/Q37283720

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical experience and critic ...... advanced renal cell carcinoma

@en

Clinical experience and critic ...... advanced renal cell carcinoma.

@nl

type

Item

label

Clinical experience and critic ...... advanced renal cell carcinoma

@en

Clinical experience and critic ...... advanced renal cell carcinoma.

@nl

prefLabel

Clinical experience and critic ...... advanced renal cell carcinoma

@en

Clinical experience and critic ...... advanced renal cell carcinoma.

@nl

P1476

Clinical experience and critic ...... advanced renal cell carcinoma

@en

P2093

Jan Schmitges

http://www.w3.org/2001/XMLSchema#string

Maxine Sun

http://www.w3.org/2001/XMLSchema#string

Paul Perrotte

http://www.w3.org/2001/XMLSchema#string

Pierre I Karakiewicz

http://www.w3.org/2001/XMLSchema#string

Shahrokh F Shariat

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

P304

43-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OAJU.S13283

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Claudio Jeldres

Firas Abdollah

P577

2011-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24198635

http://www.w3.org/2001/XMLSchema#string

P932

3818936

http://www.w3.org/2001/XMLSchema#string